BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA, Rios-Dalenz J, Iliopoulos D, Soloway RD. Serum CEA and CA 19-9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:821-824. [PMID: 2335386 DOI: 10.1002/ijc.2910450505] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, Hu JC, Hershman DL, Accordino MK, Wright JD, Vasan S, Neugut AI, Tergas A, Hu JC, Hershman DL. Serum Tumor Marker Use in Patients With Advanced Solid Tumors. J Oncol Pract 2016;12:65-6, e36-43. [PMID: 26374862 DOI: 10.1200/JOP.2015.005660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
2 Letelier P, Riquelme I, Hernández AH, Guzmán N, Farías JG, Roa JC. Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci 2016;17:E791. [PMID: 27223281 DOI: 10.3390/ijms17050791] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
3 Gourgiotis S, Kocher HM, Solaini L, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. Am J Surg. 2008;196:252-264. [PMID: 18466866 DOI: 10.1016/j.amjsurg.2007.11.011] [Cited by in Crossref: 129] [Cited by in F6Publishing: 110] [Article Influence: 9.2] [Reference Citation Analysis]
4 Okumura K, Gogna S, Gachabayov M, Felsenreich DM, McGuirk M, Rojas A, Quintero L, Seshadri R, Gu K, Dong XD. Gallbladder cancer: Historical treatment and new management options. World J Gastrointest Oncol 2021; 13(10): 1317-1335 [PMID: 34721769 DOI: 10.4251/wjgo.v13.i10.1317] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
5 Mayr C, Beyreis M, Wagner A, Pichler M, Neureiter D, Kiesslich T. Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers. Biomed Res Int. 2016;2016:4805270. [PMID: 27957497 DOI: 10.1155/2016/4805270] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bartlett DL. Gallbladder cancer. Semin Surg Oncol 2000;19:145-55. [DOI: 10.1002/1098-2388(200009)19:2<145::aid-ssu7>3.0.co;2-6] [Cited by in Crossref: 57] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
7 Wang WJ, Xu WH, Liu CZ, Rashid A, Cheng JR, Liao P, Hu H, Chu LW, Gao YT, Yu K, Hsing AW. Identification of Serum Biomarkers for Biliary Tract Cancers by a Proteomic Approach Based on Time-of-Flight Mass Spectrometry. Cancers (Basel) 2010;2:1602-16. [PMID: 24281176 DOI: 10.3390/cancers2031602] [Reference Citation Analysis]
8 Cleary SP, Dawson LA, Knox JJ, Gallinger S. Cancer of the gallbladder and extrahepatic bile ducts. Curr Probl Surg. 2007;44:396-482. [PMID: 17693325 DOI: 10.1067/j.cpsurg.2007.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
9 Liu MC, Jiang L, Hong HJ, Meng ZW, Du Q, Zhou LY, She FF, Chen YL. Serum vascular endothelial growth factors C and D as forecast tools for patients with gallbladder carcinoma. Tumour Biol 2015;36:6305-12. [PMID: 25801241 DOI: 10.1007/s13277-015-3316-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
10 Saritas AG, Gul MO, Teke Z, Ulku A, Rencuzogullari A, Aydin I, Akcam AT. Xanthogranulomatous cholecystitis: a rare gallbladder pathology from a single-center perspective. Ann Surg Treat Res 2020;99:230-7. [PMID: 33029482 DOI: 10.4174/astr.2020.99.4.230] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, Shrivastav BR, Navani S, Leal P, Roa JC, Chaerkady R, Gupta S, Chatterjee A, Pandey A, Tiwari PK. Identification of prosaposin and transgelin as potential biomarkers for gallbladder cancer using quantitative proteomics. Biochem Biophys Res Commun 2014;446:863-9. [PMID: 24657443 DOI: 10.1016/j.bbrc.2014.03.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
12 Rana S, Dutta U, Kochhar R, Rana SV, Gupta R, Pal R, Jain K, Srinivasan R, Nagi B, Nain CK. Evaluation of CA 242 as a tumor marker in gallbladder cancer. J Gastrointest Cancer. 2012;43:267-271. [PMID: 21573879 DOI: 10.1007/s12029-011-9288-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
13 Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Sci Rep 2019;9:5925. [PMID: 30976046 DOI: 10.1038/s41598-019-42392-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol. 2003;4:167-176. [PMID: 12623362 DOI: 10.1016/s1470-2045(03)01021-0] [Cited by in Crossref: 431] [Cited by in F6Publishing: 188] [Article Influence: 22.7] [Reference Citation Analysis]
15 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Deng YL, Cheng NS, Zhang SJ, Ma WJ, Shrestha A, Li FY, Xu FL, Zhao LS. Xanthogranulomatous cholecystitis mimicking gallbladder carcinoma: An analysis of 42 cases. World J Gastroenterol 2015; 21(44): 12653-12659 [PMID: 26640342 DOI: 10.3748/wjg.v21.i44.12653] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
17 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Reference Citation Analysis]
18 Qin Y, Meng L, Fu Y, Quan Z, Ma M, Weng M, Zhang Z, Gao C, Shi X, Han K. SNORA74B gene silencing inhibits gallbladder cancer cells by inducing PHLPP and suppressing Akt/mTOR signaling. Oncotarget 2017;8:19980-96. [PMID: 28212545 DOI: 10.18632/oncotarget.15301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
19 Jurcic P. Dermatomyositis as the first manifestation of gallbladder adenocarcinoma: case report and literature overview. World J Surg Oncol 2015;13:127. [PMID: 25890241 DOI: 10.1186/s12957-015-0535-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
20 Pandey D. Surgical management of gallbladder cancer. Indian J Surg 2009;71:363-7. [PMID: 23133192 DOI: 10.1007/s12262-009-0095-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
21 Sachan A, Saluja SS, Nekarakanti PK, Nimisha, Mahajan B, Nag HH, Mishra PK. Raised CA19-9 and CEA have prognostic relevance in gallbladder carcinoma. BMC Cancer. 2020;20:826. [PMID: 32867709 DOI: 10.1186/s12885-020-07334-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Wen Z, Si A, Yang J, Yang P, Yang X, Liu H, Yan X, Li W, Zhang B. Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma. HPB (Oxford). 2017;19:951-956. [PMID: 28750922 DOI: 10.1016/j.hpb.2017.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
23 Graff AE, Lewis SL, Bear JR, Van Echo DC, Dainer HM. Gallbladder Carcinoma, the Difficulty of Early Detection: A Case Report. Cureus 2016;8:e493. [PMID: 27014527 DOI: 10.7759/cureus.493] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Cho WCS. Cancer Biomarkers (An Overview). In: Hayat MA, editor. Methods of Cancer Diagnosis, Therapy, and Prognosis. Dordrecht: Springer Netherlands; 2010. pp. 21-40. [DOI: 10.1007/978-90-481-3186-0_2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
25 Agrawal S, Gupta A, Gupta S, Goyal B, Siddeek RAT, Rajput D, Chauhan U, Kishore S, Gupta M, Kant R. Role of carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 as the predictors of resectability and survival in the patients of Carcinoma Gall Bladder. J Carcinog 2020;19:4. [PMID: 33033460 DOI: 10.4103/jcar.JCar_10_20] [Reference Citation Analysis]
26 Kim M, Kim H, Han Y, Sohn H, Kang JS, Kwon W, Jang JY. Prognostic Value of Carcinoembryonic Antigen (CEA) and Carbohydrate Antigen 19-9 (CA 19-9) in Gallbladder Cancer; 65 IU/mL of CA 19-9 Is the New Cut-Off Value for Prognosis. Cancers (Basel) 2021;13:1089. [PMID: 33806265 DOI: 10.3390/cancers13051089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Li L, Ren T, Liu K, Li ML, Geng YJ, Yang Y, Li HF, Li XC, Bao RF, Shu YJ, Weng H, Gong W, Lau WY, Wu XS, Liu YB. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Front Oncol 2021;11:692647. [PMID: 34268122 DOI: 10.3389/fonc.2021.692647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J Surg Oncol. 2006;93:665-669. [PMID: 16724349 DOI: 10.1002/jso.20534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
29 Ramírez C, Suárez M, Santoyo J, Fernández J, Jiménez M, Pérez J, Bondía J, de la Fuente A. Actualización del diagnóstico y el tratamiento del cáncer de vesícula biliar. Cirugía Española 2002;71:102-11. [DOI: 10.1016/s0009-739x(02)71940-4] [Cited by in Crossref: 10] [Article Influence: 0.5] [Reference Citation Analysis]
30 Hunt TM, Waletzko MR, Knudsen JM, Atwell TD, Chupka NM. The Effectiveness of Identifying Primary Gallbladder Adenocarcinoma Utilizing Contrast-Enhanced Ultrasound: A Case Report. Journal of Diagnostic Medical Sonography 2021;37:575-83. [DOI: 10.1177/87564793211018959] [Reference Citation Analysis]
31 Abou-alfa GK, Jarnagin W, Lowery M, D'angelica M, Brown K, Ludwig E, Covey A, Kemeny N, Goodman KA, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 1373-1396.e8. [DOI: 10.1016/b978-1-4557-2865-7.00080-1] [Reference Citation Analysis]
32 Moral A, Magarzo J. Marcadores tumorales serológicos en cirugía hepatobiliopancreática. Cirugía Española 2004;76:276-83. [DOI: 10.1016/s0009-739x(04)72378-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Ofoeyeno N, Ekpenyong E, Braconi C. Pathogenetic Role and Clinical Implications of Regulatory RNAs in Biliary Tract Cancer. Cancers (Basel) 2020;13:E12. [PMID: 33375055 DOI: 10.3390/cancers13010012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999;10 Suppl 4:145-9. [PMID: 10436809 [PMID: 10436809 DOI: 10.1093/annonc/10.suppl_4.s145] [Cited by in Crossref: 73] [Cited by in F6Publishing: 2] [Article Influence: 3.2] [Reference Citation Analysis]